Author details

Full Name

JoEllyn McMillan

Affiliation

ORCID

Career Start Year

1990

Papers

103

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35680875	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.	Nature Communications	2022
34531390	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.	Nature Communications	2021
33972918	Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs.	Nanotheranostics	2021
33589798	Diagnostics for SARS-CoV-2 infections.	Nature Materials	2021
34049358	Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue.	AIDS	2021
34103484	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.	Nature Communications	2021
33450312	Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca homeostasis in skeletal muscles.	Antiviral Research	2021
33403500	Pharmacotherapeutics of SARS-CoV-2 Infections.	Journal of NeuroImmune Pharmacology	2021
34390469	Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.	Molecular Neurobiology	2021
34970611	A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection.	Front Cardiovasc Med	2021
34774454	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.	eBioMedicine	2021
32552187	Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.		2020
31742407	Synthesis and Characterization of Long-Acting Darunavir Prodrugs.	Molecular Pharmaceutics	2020
31903142	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.	Theranostics	2020
32341511	A year-long extended release nanoformulated cabotegravir prodrug.	Nat Mater	2020
31865227	Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking.	Biomaterials	2020
32640624	Adeno-Associated Viral Transfer of Glyoxalase-1 Blunts Carbonyl and Oxidative Stresses in Hearts of Type 1 Diabetic Rats.	Antioxidants	2020
31496683	Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.	International Journal of Nanomedicine	2019
30069830	Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress.	Mol Neurobiol	2019
30289818	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.	AIDS	2019
30421721	Neurotheranostics as personalized medicines.	Advanced Drug Delivery Reviews	2019
31525692	A long acting nanoformulated lamivudine ProTide.	Biomaterials	2019
30981593	The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.	Trends in Microbiology	2019
31491432	Creation of a long-acting rilpivirine prodrug nanoformulation.	J Control Release	2019
31472458	Synthesis of a long acting nanoformulated emtricitabine ProTide.	Biomaterials	2019
31266936	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice.	Nature Communications	2019
29402886	Creation of a long-acting nanoformulated dolutegravir.	Nature Communications	2018
29059541	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.	Biomaterials	2018
29879225	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment.	PLoS Pathogens	2018
30245386	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.	Biomaterials	2018
29995046	ProTide generated long-acting abacavir nanoformulations.	Chemical Communications	2018
30369055	Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery.		2018
30129397	Modulating cellular autophagy for controlled antiretroviral drug release.	Nanomedicine	2018
29476044	Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.	Journal of Pharmacology and Experimental Therapeutics	2018
29553879	Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.	Nanomedicine	2018
29518644	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.	Journal of Pharmaceutical and Biomedical Analysis	2018
29604978	Neuropathogenesis of human immunodeficiency virus infection.	Handbook of Clinical Neurology	2018
29290806	Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.	Theranostics	2018
28134625	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.	Journal of Clinical Investigation	2017
29061742	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.	Antimicrob Agents Chemother	2017
27559685	Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.	Journal of acquired immune deficiency syndromes (1999)	2017
27879160	Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.	Nanomedicine	2017
27916740	Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.		2017
28128004	Long-acting slow effective release antiretroviral therapy.		2017
26472049	The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.	Nanomedicine: Nanotechnology, Biology, and Medicine	2016
27456759	Development and characterization of a long-acting nanoformulated abacavir prodrug.	Nanomedicine	2016
26026666	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.	Antiviral Research	2015
25652894	Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines.	Nanomedicine: Nanotechnology, Biology, and Medicine	2015
25608975	Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.	Retrovirology	2015
25522973	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.	Biomaterials	2015